Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 5/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14063061 | 0.89 | ESR2 (0.70) | NR1H2ESR2HDAC1GPR119DDB1 | |
| SCHEMBL9257641 | 0.89 | NR1H2 (0.73) | NR1H2ESR2HDAC1GPR119DDB1 | |
| SCHEMBL8280135 | 0.87 | ESR2 (0.56) | NR1H2ESR2HDAC1GPR119DDB1 | |
| SCHEMBL29835137 | 0.87 | ESR2 (0.56) | NR1H2ESR2HDAC1GPR119DDB1 | |
| SCHEMBL1650164 | 0.87 | ESR2 (0.56) | NR1H2ESR2HDAC1DDB1CRBN | |
| SCHEMBL24038851 | 0.86 | HDAC1 (0.55) | NR1H2ESR2HDAC1DDB1CRBN | |
| SCHEMBL30090221 | 0.86 | HDAC1 (0.55) | NR1H2ESR2HDAC1DDB1CRBN | |
| SCHEMBL20571231 | 0.84 | ESR2 (0.53) | NR1H2ESR2HDAC1GPR119DDB1 | |
| SCHEMBL30091911 | 0.84 | HDAC1 (0.56) | NR1H2ESR2HDAC1DDB1CRBN | |
| SCHEMBL329653 | 0.84 | HDAC1 (0.56) | NR1H2ESR2HDAC1DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024199421-A1 | CYP11A1 INHIBITOR | 山东轩竹医药科技有限公司 | 2024-10-03 | — | — | WO | disclosed |
| WO-2021218755-A1 | SHP2 INHIBITOR, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 (CN) | 2021-11-04 | — | — | WO | disclosed |
| CN-107849047-B | Biphenyl derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-107849047-A | Biphenyl derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2018-03-27 | — | — | CN | disclosed |
| US-20090042862-A1 | NOVEL COMPOUNDS | BEST DESMOND JOHN | 2009-02-12 | — | — | US | disclosed |
| US-7446103-B2 | Bicyclic benzamide compound as histamine H3 receptor ligand useful in the treatment of neurological diseases | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| EP-1554243-B1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| EP-1554243-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037788-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | HRH3, HRH4, HRH1 | NR1H2 992/4885ESR2 1745/4885HDAC1 79/4885 |
| US-20090042862-A1 | NOVEL COMPOUNDS | GRIN2C, GRIN2A, GRIN2B | NR1H2 2353/4885ESR2 2404/4885HDAC1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.